China’s domestic biotech industry is becoming a global force
China’s domestic biotech industry is entering a new phase of international influence, as homegrown innovative drugs increasingly meet global clinical demand. One recent example is Dizal Pharma, a Wuxi-based biotech firm that has emerged as a model for China’s evolving pharmaceutical ambitions. On July 10, Dizal’s lung cancer drug, sunvozertinib, was officially included in the…









